These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

537 related items for PubMed ID: 22122457

  • 1. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
    Derosa G, Maffioli P.
    Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
    Simó R, Rodriguez A, Caveda E.
    Curr Drug Saf; 2010 Jul 02; 5(3):234-44. PubMed ID: 20210732
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
    Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE.
    Br J Pharmacol; 2008 Feb 02; 153(4):636-45. PubMed ID: 17906687
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus.
    Mensink M, Hesselink MK, Russell AP, Schaart G, Sels JP, Schrauwen P.
    Int J Obes (Lond); 2007 Aug 02; 31(8):1302-10. PubMed ID: 17310221
    [Abstract] [Full Text] [Related]

  • 14. Treatment of Mitochondrial Diabetes with a Peroxisome Proliferator-activated Receptor (PPAR)-gamma Agonist.
    Ninomiya H, Hirata A, Kozawa J, Nakata S, Kimura T, Kitamura T, Yasuda T, Otsuki M, Imagawa A, Kaneto H, Funahashi T, Shimomura I.
    Intern Med; 2016 Aug 02; 55(9):1143-7. PubMed ID: 27150869
    [Abstract] [Full Text] [Related]

  • 15. Targeting peroxisome proliferator-activated receptor gamma for generation of antidiabetic drug.
    Karak M, Bal NC, Bal C, Sharon A.
    Curr Diabetes Rev; 2013 Jul 02; 9(4):275-85. PubMed ID: 23746081
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
    Roberts AW, Thomas A, Rees A, Evans M.
    Curr Opin Lipidol; 2003 Dec 02; 14(6):567-73. PubMed ID: 14624133
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
    Consoli A, Formoso G.
    Diabetes Obes Metab; 2013 Nov 02; 15(11):967-77. PubMed ID: 23522285
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.